More Videos
- Genentech's Avastin Goes Primetime
- Genentech Regains "Title" As Best Biopharma Employer
- The Last Word--For Now--On Dendreon
- Barack Obama: Big Pharma's Million Dollar Man
- Roche Speaks My Language But Genentech Not So Much
- Could The Credit Crisis Help Pfizer?
- Biotech Bonanza For ImClone & Dendreon
- Dendreon, ImClone & Pfizer: Your Emails
- Lilly's "Secret" (About ImClone) Is Out--Or Is It?
- Oktoberfest For ImClone & Dendreon (Update On Mystery Bid)
- Executive Decision: Waste Management CEO David Steiner
- Lightning Round: Microsoft, Google, Dell and More
- Lightning Round OT: AIG, Home Depot and More
- CEO Sell-Offs
- Hedge Fund Pain Is Your Gain
- Cramer: This Market Can’t Be Trusted
- Your First Move For Tuesday October 14th
- Web Extra: A Few Tuesday Trades
- Pops & Drops, Alcoa, RIMM...
- Former Fed Chief Says US Now in Recession
- Printing Money = High Commodities Prices: Analyst
- Blackstone Says US Action Breaks Back of Crisis
- European Shares Rally on Bailout Action
- SABMiller Beer Volumes Rise, Warns on Year
- Plan Will Bring Markets Back to Normal: Bernanke
- European Shares Set to Extend Rally on US Plan
- South Korea Is Ready to Aid Banks as Won Jumps
- Markets Surge Ahead of US $250 Billion Bank Bailout
Text Size 
 |
Yoda |
At the end of his speech in the opening session, the outgoing president of the organization played a "Star Wars" clip with the sage saying, "Try not. Do or do not. There is no try." He was trying to make a point about the ACC's role in forging healthcare reform.
But many--especially, I suspect, folks at Merck [MRK
Loading...
()
] and Schering-Plough-[SGP
Loading...
()
] --would argue the ACC tried, but did not do when it comes to the promised "reasoned" panel discussion of the controversial Vytorin/Zetia test results.
It was standing room only in the great hall for the "showcase session," although the fire marshal shooed away people who were standing four and five deep in the wide doorways. They came to hear the data presentation and then an airing-out of the results by an ACC handpicked panel of experts.
But the second part never happened. One of the experts, Dr. Harlan Krumholz, launched into prepared remarks during which he suggested that Zetia could be nothing more than an "expensive placebo." Those are his words. Another panel member put a brief button on Dr. Krumholz's speech and that was it. No discussion. No q and a. The room, packed with by my estimate about 6,000 people, emptied out in a hurry.
Damage was done.
Credit Suisse analyst Catherine Arnold writes in a research note to clients this morning, "...the expected 'panel discussion' had almost no 'discussion', rather it seemed like a (Zetia)-bashing session...." Because of that Arnold now believes a Vytorin/Zetia "recovery" will require patience and as a result she's taking a scalpel to her earnings estimates for both companies.
Credit Suisse has done and wants to do more investment banking for MRK and SGP. And Arnold or someone on her team lives with a Schering employee.
May the sales force be with Merck and Schering-Plough.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes